Literature DB >> 34643428

Perturbing HIV-1 Ribosomal Frameshifting Frequency Reveals a cis Preference for Gag-Pol Incorporation into Assembling Virions.

Bayleigh E Benner1,2, James W Bruce1,3, Jacob R Kentala1, Magdalena Murray1, Jordan T Becker1, Pablo Garcia-Miranda1,4, Paul Ahlquist1,3, Samuel E Butcher4, Nathan M Sherer1.   

Abstract

HIV-1 virion production is driven by Gag and Gag-Pol (GP) proteins, with Gag forming the bulk of the capsid and driving budding, while GP binds Gag to deliver the essential virion enzymes protease, reverse transcriptase, and integrase. Virion GP levels are traditionally thought to reflect the relative abundances of GP and Gag in cells (∼1:20), dictated by the frequency of a -1 programmed ribosomal frameshifting (PRF) event occurring in gag-pol mRNAs. Here, we exploited a panel of PRF mutant viruses to show that mechanisms in addition to PRF regulate GP incorporation into virions. First, we show that GP is enriched ∼3-fold in virions relative to cells, with viral infectivity being better maintained at subphysiological levels of GP than when GP levels are too high. Second, we report that GP is more efficiently incorporated into virions when Gag and GP are synthesized in cis (i.e., from the same gag-pol mRNA) than in trans, suggesting that Gag/GP translation and assembly are spatially coupled processes. Third, we show that, surprisingly, virions exhibit a strong upper limit to trans-delivered GP incorporation; an adaptation that appears to allow the virus to temper defects to GP/Gag cleavage that may negatively impact reverse transcription. Taking these results together, we propose a "weighted Goldilocks" scenario for HIV-1 GP incorporation, wherein combined mechanisms of GP enrichment and exclusion buffer virion infectivity over a broad range of local GP concentrations. These results provide new insights into the HIV-1 virion assembly pathway relevant to the anticipated efficacy of PRF-targeted antiviral strategies. IMPORTANCE HIV-1 infectivity requires incorporation of the Gag-Pol (GP) precursor polyprotein into virions during the process of virus particle assembly. Mechanisms dictating GP incorporation into assembling virions are poorly defined, with GP levels in virions traditionally thought to solely reflect relative levels of Gag and GP expressed in cells, dictated by the frequency of a -1 programmed ribosomal frameshifting (PRF) event that occurs in gag-pol mRNAs. Herein, we provide experimental support for a "weighted Goldilocks" scenario for GP incorporation, wherein the virus exploits both random and nonrandom mechanisms to buffer infectivity over a wide range of GP expression levels. These mechanistic data are relevant to ongoing efforts to develop antiviral strategies targeting PRF frequency and/or HIV-1 virion maturation.

Entities:  

Keywords:  Gag; Gag-Pol; HIV; PRF; cis-acting RNA element; protease; reverse transcription; ribosomal frameshift; virion; virus assembly

Mesh:

Substances:

Year:  2021        PMID: 34643428      PMCID: PMC8754204          DOI: 10.1128/JVI.01349-21

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   6.549


  68 in total

1.  Solution structure and thermodynamic investigation of the HIV-1 frameshift inducing element.

Authors:  David W Staple; Samuel E Butcher
Journal:  J Mol Biol       Date:  2005-04-01       Impact factor: 5.469

Review 2.  How retroviruses select their genomes.

Authors:  Victoria D'Souza; Michael F Summers
Journal:  Nat Rev Microbiol       Date:  2005-08       Impact factor: 60.633

3.  Interactions between HIV Rev and nuclear import and export factors: the Rev nuclear localisation signal mediates specific binding to human importin-beta.

Authors:  B R Henderson; P Percipalle
Journal:  J Mol Biol       Date:  1997-12-19       Impact factor: 5.469

4.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

5.  Proline residues within spacer peptide p1 are important for human immunodeficiency virus type 1 infectivity, protein processing, and genomic RNA dimer stability.

Authors:  Melissa K Hill; Miranda Shehu-Xhilaga; Suzanne M Crowe; Johnson Mak
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

6.  Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles.

Authors:  V Karacostas; E J Wolffe; K Nagashima; M A Gonda; B Moss
Journal:  Virology       Date:  1993-04       Impact factor: 3.616

7.  A dominant block to HIV-1 replication at reverse transcription in simian cells.

Authors:  Carsten Münk; Stephanie M Brandt; Ginger Lucero; Nathaniel R Landau
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-04       Impact factor: 11.205

Review 8.  Programmed ribosomal frameshifting in HIV-1 and the SARS-CoV.

Authors:  Ian Brierley; Francisco J Dos Ramos
Journal:  Virus Res       Date:  2005-11-28       Impact factor: 3.303

9.  HIV-1 Gag co-opts a cellular complex containing DDX6, a helicase that facilitates capsid assembly.

Authors:  Jonathan C Reed; Britta Molter; Clair D Geary; John McNevin; Julie McElrath; Samina Giri; Kevin C Klein; Jaisri R Lingappa
Journal:  J Cell Biol       Date:  2012-07-30       Impact factor: 10.539

10.  The Race against Protease Activation Defines the Role of ESCRTs in HIV Budding.

Authors:  Mourad Bendjennat; Saveez Saffarian
Journal:  PLoS Pathog       Date:  2016-06-09       Impact factor: 6.823

View more
  2 in total

Review 1.  Shiftless, a Critical Piece of the Innate Immune Response to Viral Infection.

Authors:  William Rodriguez; Mandy Muller
Journal:  Viruses       Date:  2022-06-20       Impact factor: 5.818

Review 2.  Advances in HIV-1 Assembly.

Authors:  Grigoriy Lerner; Nicholas Weaver; Boris Anokhin; Paul Spearman
Journal:  Viruses       Date:  2022-02-26       Impact factor: 5.048

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.